PERTH, Australia – Singular Health Group Ltd. was awarded AU$50,000 (US$37,000) in funding from Australia’s Commonwealth Scientific and Industrial Research Organization’s (CSIRO) Kick-Start program to undertake a research project to develop artificial intelligence (AI)-based tools to automatically design patient-specific cranial implants. The AI will be integrated into Singular Health’s surgical planning software for editing before the cranial implants are 3D printed.
Cerecin Inc. has raised $40 million in an oversubscribed round of financing, paving the way for a potential listing in South Korea. Proceeds of the financing will fund the expansion of the company’s current studies and support the planning and initiation of a global phase III study of its lead candidate, tricaprilin, in Alzheimer’s disease.
DNA Script SAS nabbed $165 million in a series C fundraising round to support commercialization of the company’s Syntax platform and expand its portfolio of products powered by enzymatic DNA synthesis. DNA Script has raised a total of $280 million to date.
Precision cancer care company Simbiosys Inc. has raised $15 million to accelerate development of its Tumor Scope software platform for management of solid tumors. The application enables oncologists to virtualize cancer tumors and simulate a patient’s response to specific drug therapies by combining artificial intelligence with biophysical simulations. The technology models the impact of drug delivery, drug sensitivity, metabolism and spatial heterogeneity and provides data that can be used to inform individual treatment plans.
Quanta Therapeutics Inc., a company developing therapies for RAS-driven cancers, closed $60 million in series C financing led by Surveyor Capital and Vida Ventures. The South San Francisco-based company said it would use proceeds from the financing to advance oncology-focused programs targeting RAF1 and KRAS through clinical candidate selection, IND filing and on to initial proof of concept.